Drug Type Small molecule drug |
Synonyms Upacicalcet + [3] |
Target |
Action modulators |
Mechanism CaSR modulators(Calcium sensing receptor modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (23 Jun 2021), |
Regulation- |
Molecular FormulaC11H14ClN3O6S |
InChIKeyLHEYGVSDVBEYQF-QMMMGPOBSA-N |
CAS Registry1333218-50-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Upacicalcet Sodium Hydrate | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hyperparathyroidism, Secondary | Japan | 23 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperparathyroidism, Secondary | Phase 3 | Serbia | 28 Apr 2023 | |
Hyperparathyroidism, Secondary | Phase 3 | Portugal | 28 Apr 2023 | |
Hyperparathyroidism, Secondary | Phase 3 | United States | 28 Apr 2023 | |
Hyperparathyroidism, Secondary | Phase 3 | Bulgaria | 28 Apr 2023 | |
Hyperparathyroidism, Secondary | Phase 3 | Poland | 28 Apr 2023 | |
Hyperparathyroidism, Secondary | Phase 3 | Spain | 28 Apr 2023 | |
Kidney Failure, Chronic | Phase 3 | Spain | 28 Apr 2023 | |
Hyperparathyroidism | Phase 3 | - | - | |
Hyperparathyroidism | Phase 3 | - | - | |
Hyperparathyroidism | Phase 3 | - | - |
Not Applicable | - | pckxncmkhp(rufljtlhlq) = wvwpaknerp jpfgajozfr (vpcozmokgp ) | - | 19 Oct 2020 | |||
pckxncmkhp(rufljtlhlq) = hmjlyvvqfz jpfgajozfr (vpcozmokgp ) |